BRAF and melanoma: Indeed, in TT-treated patients with BRAF-mutant melanoma, it has been shown that the acquisition of a dedifferentiated cell state characterized by the expression of mesenchymal genes, and genes involved in cell adhesion and migration, ECM remodeling and wound healing is not only typical of resistance to TT but also of ICB resistance [6, 33, 39, 84].